Skip to main content
Account

Table 3 Characterizations of PLV nanoparticles

From: Synergistically Enhanced Inhibitory Effects of Pullulan Nanoparticle-Mediated Co-Delivery of Lovastatin and Doxorubicin to Triple-Negative Breast Cancer Cells

Sample

DS

LCL%

LCD%

EE%

Zeta potential (mV)

Average size (nm)

PDI

PLV NP (1/2)

7.87%

15.99%

− 11.66

177.2

0.138

PLV NP (1/3)

3.58%

8.09%

− 10.51

189.7

0.160

PLV NP (1/4)

3.06%

7.01%

− 8.30

219.8

0.050

PLV/DXR NP

7.87%

15.69%

1.93%

20.92%

− 10.51

225.6

0.073

FITC-loaded PLV/DXR NP

7.87%

− 15.09

253.8

0.078

Navigation